Adamis Pharmaceuticals Announces Investor Update Live Webcast

Adamis Pharmaceuticals Announces Investor Update Live Webcast 
SAN DIEGO, CA -- (Marketwired) -- 06/12/14 --  Adamis Pharmaceuticals
Corp. (NASDAQ: ADMP) ("the Company") will host a live webcast on
Monday, June 16, 2014 at 4:15pm ET to provide a business update
concerning the Company's recent corporate developments. The Company's
President and CEO, Dr. Dennis Carlo, will host the call. 
Date: Monday, June 16, 2014 
Time: 4:15pm ET (1:15pm PT) 
Webcast link: 
A webcast archive will be available approximately 30 minutes after
the live webcast using the same link. 
About Adamis Pharmaceuticals Corporation 
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical
company focused on developing and commercializing products in the
therapeutic areas of respiratory disease, allergy, oncology and
immunology. The company's current specialty pharmaceutical product
candidates include the Epinephrine Injection PFS syringe product for
use in the emergency treatment of anaphylaxis, APC-1000 and APC-5000
for the treatment of asthma and chronic obstructive pulmonary
disease, and APC-3000, an HFA inhaled nasal steroid product for the
treatment of allergic rhinitis. The company's vaccine product
candidates and cancer drug product candidates under research and
development include TeloB-VAX, a cell-based therapeutic cancer
vaccine and three drugs, APC-100, APC-200, and APC-300, for the
treatment of prostate cancer. 
Forward Looking Statements 
This press release may contain forward-looking statements that relate
to future events or our future results of operations or future
financial performance, including, but not limited to the following
statements: the ability to fund future product development and
business operations; future revenues expected from any of the
company's product candidates, assuming that they are developed and
approved for marketing by the FDA and other regulatory authorities;
our ability to complete any future acquisitions of products, product
candidates or technologies; and the intellectual property protection
that may be afforded by any patents or patent applications relating
to the company's technology. Certain of these risks, uncertainties,
and other factors are described in greater detail in Adamis' filings
from time to time with the SEC, which Adamis strongly urges you to
read and consider, all of which are available free of charge on the
SEC's web site at Except as required by law,
Adamis expressly disclaims any obligation to update any
forward-looking statements. 
Adamis Contacts 
Mark Flather
Director, Investor Relations & Corporate Communications
Adamis Pharmaceuticals Corp.
Tel: 858- 412-7951
External Investor Relations 
Mark Gundy
(972) 240-1873 
Press spacebar to pause and continue. Press esc to stop.